CEP-7055 is a potent vascular endothelial growth factor receptor 2 (VEGF-R2) tyrosine kinase inhibitor with strong anti-tumor activity in multiple in vivo tumor models; it has entered Phase I clinical trials as a water-soluble N,N-dimethylglycine ester prodrug (compound 40) to improve aqueous solubility and oral bioavailability.